Willingness of Women with Endometriosis Planning to Undergo IVF to Participate in a Randomized Clinical Trial and the Effects of the COVID-19 Pandemic on Potential Participation

Shannon Pretzel, Katherine Kuhn, Lubna Pal, Alex J. Polotsky, Alex Polotsky, Hugh S Taylor, Heping Zhang, Jared Robins, Jared C. Robins, Steven L Young, Nanette Santoro
Reproductive sciences (Thousand Oaks, Calif.) · 2021 · vol. 29(2) , pp. 620–626 · doi:10.1007/s43032-021-00705-0 · PMID:34363198 · PMC8345905 · W3193103507
article OA: gold CC0 ⤵ 1 in-corpus citation
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-07 ⓘ

A survey found that electronic medical record-based recruitment for a GnRH antagonist trial in women with endometriosis is feasible, though low in yield, with COVID-19 delays not significantly impacting participation interest.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

The study investigated feasibility of recruiting women from an EMR-based approach for the PREGnant randomized trial, which tests whether 60 days of pre-IVF elagolix versus placebo improves live birth in women with documented endometriosis planning IVF, and assessed how COVID-19 treatment delays might affect willingness. Using UCHealth EPIC/REDCap, the authors identified 212 eligible women with endometriosis and concurrent infertility, emailed a six-question survey, and received responses from 76 (36%); after exclusions, 70 reported endometriosis and 29 planned fertility treatment, with 19 planning IVF, all 19 expressing interest in participation. COVID-19 delays were not considered by 8/19, while 11 reported they would “somewhat” affect their decision; none reported they would not consider participation due to COVID-19. A key limitation is the low overall recruitment yield driven by the EMR-to-survey response rate and the subset planning IVF. This paper is centrally about endometriosis — it evaluates EMR-based recruitment and participation willingness for a trial of elagolix pre-treatment in women with endometriosis planning IVF, including COVID-19 effects on enrollment interest.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

COVID-19 Endometriosis Fertility Agents, Female Fertilization in Vitro Health Knowledge, Attitudes, Practice Hormone Antagonists Infertility, Female Patient Selection Research Subjects Adolescent Adult Choice Behavior Double-Blind Method Electronic Health Records Endometriosis Endometriosis Endometriosis Female Fertility Agents, Female Fertility Agents, Female

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (19)

Cited by (1)

Source provenance

europepmc
last seen: 2026-06-23T06:15:44.889181+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:24:26.422845+00:00
License: CC0 · commercial use OK